Chiome Bioscience (TSE:4583) ROE % Adjusted to Book Value : -12.17% (As of Jun. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Chiome Bioscience ROE % Adjusted to Book Value?

Chiome Bioscience's ROE % for the quarter that ended in Jun. 2024 was -89.71%. Chiome Bioscience's PB Ratio for the quarter that ended in Jun. 2024 was 7.37. Chiome Bioscience's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 was -12.17%.

Chiome Bioscience ROE % Adjusted to Book Value Historical Data

The historical data trend for Chiome Bioscience's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chiome Bioscience ROE % Adjusted to Book Value Chart

Chiome Bioscience Annual Data

Trend

Mar14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-20.70

-19.13

-14.09

-14.03

-13.48

Chiome Bioscience Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-15.93	-13.82	-16.59	-15.82	-12.17

Competitive Comparison of Chiome Bioscience's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Chiome Bioscience's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chiome Bioscience's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chiome Bioscience's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Chiome Bioscience's ROE % Adjusted to Book Value falls into.

Chiome Bioscience ROE % Adjusted to Book Value Calculation

Chiome Bioscience's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-82.76%	/	6.14
	=	-13.48%

Chiome Bioscience's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-89.71%	/	7.37
	=	-12.17%

Chiome Bioscience ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Chiome Bioscience's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Chiome Bioscience Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chiome Bioscience Inc (TSE:4583) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

Sumitomo Fudosan Nishi-shinjuku Building No.6, 3-12-1, Honmachi, Shibuya-ku, Tokyo, JPN, 151-0071

Website

http://www.chiome.co.jp

Chiome Bioscience Inc is a Japanese based company engaged in the manufacture and sale of antibody drugs through the Autonomous Diversifying Library System. The business activity of the group is operated through Drug Discovery Alliance, Lead Antibody Licensing, and Licensing Out Platform Technology segments. The Drug Discovery Alliance segment partners with pharmaceutical companies to develop and create lead antibody drugs. The Lead Antibody Licensing Out segment is engaged in the production of specific antibodies against antigens and early licensing out to pharmaceutical manufacturers and the Licensing Out Platform Technology segment conducts research and development through the ADLib System. Geographically all the activities are functioned through Japan.

Chiome Bioscience Headlines

No Headlines